Cevostamab  (Synonyms: BFCR 4350A; RG 6160; RO 7187797)

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells^[1][2].

FcRH5; CD3^[1][2]

Cevostamab shows a dose-dependent and robust killing of B cells and bone marrow plasma cells from peripheral blood mononuclear cell (PBMC)/BMMC samples from cynomolgus monkey^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cevostamab (0.5 mg/kg; i.v.; once weekly for ) suppresses the growth of established MOLP-2 tumors in mice reconstituted with human immune cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2249888-53-5

Liquid

Colorless to light yellow

[Cevostamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li J, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell. 2017 Mar 13;31(3):383-395.  [Content Brief]

  [2]. Hosny M, et al. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J Clin Med. 2021 Oct 6;10(19):4593.  [Content Brief]